Drug intelligence / Profile preview

TCAP

Development stage: Preclinical
Modality: Peptides

Overview

TCAP refers to the **teneurin C-terminal associated peptide** or **TCAP-1**, a bioactive neuropeptide sequence found at the C-terminus of the teneurin protein family. TCAP-1 has been investigated for its potential neuromodulatory, anxiolytic, and behavioral effects, such as reducing stress- and addiction-related behaviors. In preclinical and patent literature, TCAP-1 is examined for possible therapeutic use in neuropsychiatric and addictive disorders, including opioid addiction. The mechanism of action is not fully defined but is believed to involve modulation of corticotropin-releasing factor signaling and regulation of glutamatergic and opioid-related neurocircuitry[2].

Other names: teneurin C-terminal associated peptideteneurin C-terminal associated peptide-1TCAP-1TCAP1TCAP 1

Targets

CRHR (Corticotropin-releasing hormone receptors)LPHN (Latrophilin receptor family)

Beyond the preview

Go deeper on TCAP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TCAP.

Explore the full profile